Mednax Inc MD shares came under pressure Friday, dipping about 4 percent after Paul Singer's Elliott Associates declared a reduction in stake held in the company.
The Analyst
Leerink analyst Ana Gupte upgraded shares of Mednax from Market Perform to Outperform, citing margin turnaround, improvement in share gains at its neonatal segment and sell-off following the Elliott news, which she views as a buying opportunity. The analyst hiked the price target from $52 to $56.
The Thesis
Notwithstanding the "secularly tepid demand" for neonatal, Mednax is seeing outsized share gains, as MD-specific strategies are leading to volume growth in the low- to mid-single digits, Gupte said in a Monday note. The turnaround at anesthesia could drive about 120 basis point of margin expansion in 2019 and 2020, the analyst said.
Citing the anesthesia turnaround and neonatal volume growth, Gupte said her upwardly revised 2019 revenue and EBITDA estimates of $3,935 million and $654 million, respectively are above consensus. The 2020 revenue and EBITDA estimates of $4,273 million and $727 million, are also above consensus, she added.
The analyst said Mednax' Q3 guidance looks achievable. Free cash flow of $426 million, with a yield of 11 percent, is also attractive.
The Price Action
Along with Friday's sell-off, Mednax shares have shed about 15 percent year-to-date. At time of writing, the stock was up 2.8 percent to $46.89 Monday afternoon.
Related Links:
Where To Be With Health Care ETFs
5 Key Reasons To Invest In Mednax
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
